K
Kristian Wachtell
Researcher at Oslo University Hospital
Publications - 310
Citations - 17618
Kristian Wachtell is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Left ventricular hypertrophy & Blood pressure. The author has an hindex of 60, co-authored 292 publications receiving 15898 citations. Previous affiliations of Kristian Wachtell include Veterans Health Administration & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Anne B. Rossebø,Terje R. Pedersen,Kurt Boman,Philippe Brudi,John C. Chambers,Kenneth Egstrup,Eva Gerdts,Christa Gohlke-Bärwolf,Ingar Holme,Y. Antero Kesäniemi,William Malbecq,Christoph A. Nienaber,Simon Ray,Terje Skjærpe,Kristian Wachtell,Ronnie Willenheimer +15 more
TL;DR: Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aorti stenosis, and such therapy reduced the incidence of isChemic cardiovascular events but not events related to aorting stenosis.
Journal ArticleDOI
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study
Kristian Wachtell,Mika Lehto,Eva Gerdts,Michael H. Olsen,Björn Hornestam,Björn Dahlöf,Hans Ibsen,Stevo Julius,Sverre E. Kjeldsen,Lars H Lindholm,Markku S. Nieminen,Richard B. Devereux +11 more
TL;DR: The novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.
Journal ArticleDOI
Prognostic significance of left ventricular mass change during treatment of hypertension
Richard B. Devereux,Kristian Wachtell,Eva Gerdts,Krister K. Boman,Markku S. Nieminen,Vasilios Papademetriou,Jens Rokkedal,Katherine E. Harris,Peter Aurup,Björn Dahlöf +9 more
TL;DR: In patients with essential hypertension and baseline electrocardiographic LV hypertrophy, lower LV mass during antihypertensive treatment is associated with lower rates of clinical end points, additional to effects of blood pressure lowering and treatment modality.
Journal ArticleDOI
A Call to Action and a Lifecourse Strategy to Address the Global Burden of Raised Blood Pressure on Current and Future Generations: The Lancet Commission on Hypertension
Michael H. Olsen,Michael H. Olsen,Sonia Y. Angell,Samira Asma,Pierre Boutouyrie,Dylan Burger,Julio A. Chirinos,Albertino Damasceno,Christian Delles,Anne Paule Gimenez-Roqueplo,Anne Paule Gimenez-Roqueplo,Dagmara Hering,Patricio Lopez-Jaramillo,Fernando Martinez,Vlado Perkovic,Ernst Rietzschel,Giuseppe Schillaci,Aletta E. Schutte,Angelo Scuteri,James E. Sharman,Kristian Wachtell,Ji-Guang Wang +21 more
TL;DR: The Commission has identified ten essential and achievable goals and ten accompanying, mutually additive, and synergistic key actions that—if implemented effectively and broadly—will make substantial contributions to the management of blood pressure globally.
Journal ArticleDOI
Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Losartan Intervention for Endpoint Reduction in Hypertension Study
Hans Ibsen,Michael H. Olsen,Kristian Wachtell,Knut Borch-Johnsen,Lars H Lindholm,Carl Erik Mogensen,Björn Dahlöf,Richard B. Devereux,Ulf de Faire,F Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Ying Wan +16 more
TL;DR: Monitoring of albuminuria should be an integrated part of the management of hypertension if it is not decreased by the patient’s current antihypertensive and other treatment, and further intervention directed toward blood pressure control and other modifiable risks should be considered.